Over-expression of CEP55 Predicts Favorable Prognosis in Colorectal Cancer Patients with Lymph Node Involvement.

BACKGROUND/AIM:To characterize the potential roles of CEP55 in colorectal cancer development and assess its eligibility as a prognostic diagnosis tool for colorectal cancer.PATIENTS AND METHODS:Immunohistochemical (IHC) analysis of CEP55 immunoreactivity in 166 cancer specimens from colorectal cancer patients.RESULTS:CEP55 was not found to statistically significantly affect different patient clinical parameters. Multivariate analysis illustrated that patients with N stage (1+2) colorectal cancer and high CEP55 expression had a significantly lower five-year survival rate than patients with N stage (1+2) colorectal cancer and low CEP55 expression.CONCLUSION:There is a correlation between CEP55 and advanced N-stage colorectal cancer. Thus, CEP55 may be a potential diagnostic biomarker for colorectal cancer patients.